Histone deacetylase inhibitor scriptaid induces cell cycle arrest and epigenetic change in colon cancer cells

International Journal of Oncology

Volumn 33, Issue 4, 2008, Pages 767-776

  Lee, Eun Ju ^a   Lee, Bo Bin ^a   Kim, Soon Ja ^a   Park, Yong Doo ^b   Park, Joobae ^a,c   Kim, Duk Hwan ^a,c  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b TSINGHUA UNIVERSITY   (China)

^c Samsung Medical Center   (South Korea)

Author keywords

Colorectal cancer; Growth suppression; Histone; Methylation; Scriptaid

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; PROTEIN P16; TRICHOSTATIN A;

ANALYTICAL EQUIPMENT; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL GROWTH; CHROMATIN IMMUNOPRECIPITATION; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEMETHYLATION; DRUG EFFICACY; ENZYME MODIFICATION; EPIGENETICS; EUCHROMATIN; FLOW CYTOMETRY; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; UNINDEXED SEQUENCE;

APOPTOSIS; AZACITIDINE; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DNA METHYLATION; ENZYME INHIBITORS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P16; HISTONE DEACETYLASES; HUMANS; HYDROXYLAMINES; PROMOTER REGIONS (GENETICS); QUINOLINES;

EID: 54049130432     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo_00000063     Document Type: Article

References (26)

1. Esteller M, Corn PG, Baylin SB and Herman JG: A gene hypermethylation profile of human cancer. Cancer Res 61: 3225-3229, 2001.
2. Fahrner JA, Eguchi S, Herman JG and Baylin SB: Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res 62: 7213-7218, 2002.
3. Nguyen CT, Weisenberger DJ, Velicescu M, Gonzales FA, Lin JC, Liang G and Jones PA: Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2′-deoxycytidine. Cancer Res 62: 6456-6461, 2002.
4. Bachman KE, Park BH, Rhee I, et al: Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell 3: 89-95, 2003.
5. Nakayama J, Rice JC, Strahl BD, Allis CD and Grewal SI: Role of histone H3 lysine 9 methylation in epigenetic control of heterochromatin assembly. Science 292: 110-113, 2001.
6. Sims RJ III, Nishioka K and Reinberg D: Histone lysine methylation: a signature for chromatin function. Trends Genet 19: 629-639, 2003.
7. Kondo Y, Shen LL and Issa JP: Critical role of histone modification in tumor suppressor gene silencing in colorectal cancer. Mol Cell Biot 23: 206-215, 2003.
8. Liu T, Ku1jaca S, Tee A and Marshall GM: Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rev 32: 157-165, 2006.
9. Monneret C: Histone deacetylase inhibitors. Eur J Med Chem 40: 1-13, 2005.
10. Su GH, Sohn TA, Ryu B and Kern SE: A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Res 60: 3137-3142, 2000.
11. Keen JC, Yan L, Mack KM, Pettit C, Smith D, Sharma D and Davidson NE: A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine. Breast Cancer Res Treat 81: 177-186, 2003.
12. Takai N, Ueda T, Nishida M, Nasu K and Narahara H: A novel histone deacetylase inhibitor, Scriptaid, induces growth inhibition, cell cycle arrest and apoptosis in human endometrial cancer and ovarian cancer cells. Int J Mol Med 17: 323-329, 2006.
13. Herman JG, Graff JR, Myöhänen S, Nelkin BD and Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826, 1996.
14. Yang YH, Dudoit S, Luu P, Lin DM, Peng V, Ngai J and Speed TP: Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 30: e15, 2002.
15. McGarvey KM, Fahrner JA, Greene E, Martens J, Jenuwein T and Baylin SB: Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res 66: 3541-3549, 2006.
16. Cameron EE, Bachman KE, Myöhänen S, Herman JG and Baylin SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21: 103-107, 1999.
17. Richon VM, Sandhoff TW, Rifkind RA and Marks PA: Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97: 10014-10019, 2000.
18. Johnstone RW and Licht JD: Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4: 13-18, 2003.
19. Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT and Barrett JC: KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 268: 884-886, 1995.
20. Iivanainen E, Paatero I, Heikkinen SM, et al: Intra- and extracellular signaling by endothelial neuregulin-1. Exp Cell Res 313: 2896-2909, 2007.
21. Zhang X, Groopman JE and Wang JF: Extracellular matrix regulates endothelial functions through interaction of VEGFR-3 and integrin alpha5beta1. J Cell Physiol 202: 205-214, 2005.
22. Chambers AE, Banerjee S, Chaplin T, Dunne J, Debernardi S, Joel SP and Young BD: Histone acetylation-mediated regulation of genes in leukaemic cells. Eur J Cancer 39: 1165-1175, 2003.
23. Mitsiades CS, Mitsiades NS, McMullan CJ, et al: Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 101: 540-545, 2004.
24. Sasakawa Y, Naoe Y, Sogo N, et al: Marker genes to predict sensitivity to FK228, a histone deacetylase inhibitor. Biochem Pharmacol 69: 603-616, 2005.
25. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG and Davidsen SK: Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2: 151-163, 2003.
26. Gui CY, Ngo L, Xu WS, Richon VM and Marks PA: Histone deacetylase (HDAC) inhibitor activation of p2lWAF1 involves changes in promoter-associated proteins, including HDAC1 Proc Natl Acad Sci USA 101: 1241-1246, 2004.